Skip to main content
. 2019 Oct 8;2019(10):CD001408. doi: 10.1002/14651858.CD001408.pub2

Kanovsky 2004.

Methods Method of randomisation: children were randomly allocated "using a computer system"
Blinding: participants and study personnel blinded to the intervention
Intention‐to‐treat analysis: no
Loss of follow‐up: no losses to follow‐up
Unit of analysis: lower limb for local measures and child for global measures
Participants Place: 3 centres in the Czech Republic and 2 in Slovakia
Period of study: not described
Number assigned: 52
Number assessed: 52
  • 26 BoNT‐A group

  • 26 placebo group


Inclusion criteria:
  • Ambulatory children with diplegic CP

  • Age 2 to 7 years

  • Potential to benefit from the injection of BoNT‐A to the gastrocnemius muscle


Exclusion criteria:
  • Fixed contractures

  • Need for multilevel BoNT‐A injections

  • Previous surgery to the affected limbs or perceived need for surgery within the next 6 months

  • Previous BoNT‐A injections within the previous 9 months

  • Previous phenol treatment for lower limb spasticity


Age:
  • BoNT‐A group (mean/SD): 5.1/1.3 years

  • Placebo group (mean/SD): 4.2/1.5 years


Gender:
  • BoNT‐A group: 16 males; 10 females

  • Placebo group: 13 males; 13 females


Motor distribution:
  • All children were diplegic


GMFCS:
  • Not described, but according to inclusion criteria presumably all were GMFCS I, II, or III

Interventions BoNT‐A group:
  • Single BoNT‐A injection into the gastrocnemius muscles (abobotulinumtoxinA) 30 U/kg

  • Children continued to receive regular physiotherapy and to use walking aids and orthoses, as appropriate


Placebo group:
  • Single placebo injection into the gastrocnemius muscles

  • Children continued to receive regular physiotherapy and to use walking aids and orthoses, as appropriate

Outcomes Length of follow‐up:
  • Follow‐up of 16 weeks

  • Assessments at baseline and weeks 4, 8, and 16 post‐treatment


Primary outcomes:
  • Videographic gait assessment

  • Gross Motor Function Measure

  • Subjective functional assessment

  • Adverse events

Notes Comment: none
Source of funding: sponsored by Ipsen Limited
Conflicts of interest: not reported, but the funding mentioned above could be considered as a possible conflict of interest
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Comment: randomisation was done "using a computer system"
Allocation concealment (selection bias) Low risk Comment: central allocation
Blinding of participants and personnel (performance bias) 
 All outcomes Low risk Comment: both participants and personnel were blinded
Blinding of outcome assessment (detection bias) 
 All outcomes Low risk Comment: outcome assessors were blinded
Incomplete outcome data (attrition bias) 
 All outcomes Low risk Comment: no missing outcome data
Selective reporting (reporting bias) Unclear risk Comment: study protocol not available. It appears that the relevant outcomes were addressed.
Other bias Low risk Comment: no other sources of bias identified